In this issue:
OS of CDK4/6 inhibitor + aromatase inhibitor in hormone receptor+, HER2−metastatic breast cancer
Early vs. deferred CDK4/6 inhibitor use in advanced breast cancer
Medication-related jaw osteonecrosis in breast cancer patients
Trastuzumab deruxtecan in HER2+ advanced breast cancer ± brain metastases
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
OS with pembrolizumab in early-stage triple-negative breast cancer
Axillary clearance and chemotherapy in oestrogen receptor+, HER2− breast cancer
CBD oil for scan-related anxiety in advanced breast cancer
Neoadjuvant nab-paclitaxel vs. docetaxel-carboplatin, with trastuzumab-pertuzumab, in HER2+ early breast cancer
Role of cardiotoxic therapy and cardiovascular risk factors in cardiac dysfunction in breast cancer survivors
Please login below to download this issue (PDF)